Trevi Therapeutics price target raised to $24 from $23 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company provided updates across Haduvio’s development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program – as well as advance into Phase 2b for refractory chronic cough – in the first half of 2026. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and Oppenheimer sees meaningful upside as Haduvio’s momentum toward commercial builds for a growing group of poorly served chronic cough indications.